Wealth Effects’s GSK GSK Stock Holding History

Wealth Effects’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-4,600	Closed	-$250K	–	190
2022 Q2	$250K	Buy	+4,600	New	+$254K	0.15%	142

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wealth Effects's GSK Position: Q3 2022 in Review

Wealth Effects sold out of GSK (GSK) in Q3 2022, closing a stake of 4,600 shares — an estimated $250K sold.

Wealth Effects first reported a position in GSK in Q2 2022 and held it in 1 quarter. The position peaked at $250K in Q2 2022. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Wealth Effects reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Wealth Effects sold 4,600 GSK shares in Q3 2022, an estimated $250K.
Wealth Effects first reported a position in GSK in Q2 2022 and held it in 1 quarter.
Wealth Effects's GSK position peaked at $250K in Q2 2022.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Wealth Effects's 13F filing for Q3 2022, filed 14 Nov 2022.